Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) were up 2.6% on Friday . The company traded as high as $2.78 and last traded at $2.76. Approximately 329,049 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 5,027,464 shares. The stock had previously closed at $2.69.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. D. Boral Capital reissued a "buy" rating and set a $30.00 target price on shares of ImmunityBio in a research note on Friday, December 20th. EF Hutton Acquisition Co. I raised ImmunityBio to a "strong-buy" rating in a report on Wednesday, October 23rd.
Get Our Latest Analysis on IBRX
ImmunityBio Price Performance
The business has a fifty day moving average price of $4.40 and a 200 day moving average price of $4.62. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -3.02 and a beta of 0.86.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in IBRX. Victory Capital Management Inc. lifted its holdings in ImmunityBio by 16.0% in the 2nd quarter. Victory Capital Management Inc. now owns 19,953 shares of the company's stock valued at $126,000 after acquiring an additional 2,746 shares during the last quarter. Wealth Effects LLC lifted its stake in ImmunityBio by 3.4% during the third quarter. Wealth Effects LLC now owns 90,500 shares of the company's stock valued at $337,000 after purchasing an additional 3,000 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in ImmunityBio by 8.4% during the third quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company's stock valued at $178,000 after purchasing an additional 3,722 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in ImmunityBio by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock worth $99,000 after buying an additional 4,545 shares during the last quarter. Finally, Courier Capital LLC grew its position in ImmunityBio by 50.0% in the third quarter. Courier Capital LLC now owns 30,000 shares of the company's stock worth $112,000 after buying an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company's stock.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Recommended Stories
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
